Peptide field guide
DOTATATE
A somatostatin receptor targeting peptide (octreotate derivative) used as the targeting component in peptide receptor radionuclide therapy (PRRT), including 177Lu-DOTATATE for neuroendocrine tumors.
What it is
DOTATATE (often expanded as DOTA-Tyr3-octreotate) is a somatostatin receptor (SSTR) targeting peptide.
In practice, most people encounter it as part of radiolabeled PRRT drugs, where DOTATATE is linked to a chelator (DOTA) that holds a radioactive isotope such as lutetium-177.
Why people care
Some neuroendocrine tumors (NETs) express somatostatin receptors at high levels.
DOTATATE acts like a targeting ligand that can help deliver a payload (radiation, in the PRRT setting) more selectively to receptor-positive tumors.
How it works (high level)
- DOTATATE binds somatostatin receptors, especially SSTR2, on tumor cells.
- The radiolabeled complex delivers radiation locally after binding and internalization.
The peptide provides targeting. The isotope provides the cytotoxic effect.
Evidence landscape
DOTATATE-based PRRT (notably 177Lu-DOTATATE) is supported by clinical trial and real-world evidence in neuroendocrine neoplasms.
Evidence quality and outcomes depend strongly on:
- receptor expression (often assessed with somatostatin receptor imaging)
- tumor grade and proliferation (for example Ki-67)
- disease burden and prior therapies
Latest updates
- 2026-03-23: A large Japanese multicenter retrospective study (422 patients) reported real-world outcomes for 177Lu-DOTATATE PRRT in advanced neuroendocrine neoplasms.
Safety reality
PRRT has known risks including hematologic toxicity and, less commonly, renal toxicity. Actual risk depends on prior treatments, baseline marrow reserve, kidney function, and cumulative dose.
This page is informational and does not substitute for medical advice.
References
- Okamoto K, et al. Efficacy and safety of peptide radionuclide therapy with 177Lu-DOTATATE in Japanese patients with advanced neuroendocrine neoplasm: a multicenter retrospective study (JON2203-N). J Gastroenterol. (2026).